CXCL12 expression by healthy and malignant ovarian epithelial cells

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Machelon, Véronique ^a   Gaudin, Françoise ^a   Camilleri Broët, Sophie ^b,c   Nasreddine, Salam ^a   Bouchet Delbos, Laurence ^a   Pujade Lauraine, Eric ^b   Alexandre, Jerôme ^b   Gladieff, Laurence ^d   Arenzana Seisdedos, Fernando ^e   Emilie, Dominique ^a,f   Prévot, Sophie ^f   Broët, Philippe ^b   Balabanian, Karl ^a  

^a Universite Paris Sud   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c Cabinet de Pathologie Tolbiac   (France)

^d INSTITUT CLAUDIUS REGAUD   (France)

^e INSTITUT PASTEUR   (France)

^f HÔPITAL ANTOINE BÉCLÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; STROMAL CELL DERIVED FACTOR 1; CXCL12 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ADVANCED CANCER; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; EPITHELIUM CELL; EPITHELIUM TUMOR; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVARY; OVARY CANCER; OVARY FOLLICLE; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; UTERINE TUBE; AGED; CLINICAL TRIAL; COHORT ANALYSIS; EVALUATION; HEALTH; METABOLISM; MIDDLE AGED; NEOPLASM; OVARY TUMOR; PATHOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS;

ADULT; AGED; CHEMOKINE CXCL12; CLINICAL TRIALS, PHASE III AS TOPIC; COHORT STUDIES; EPITHELIAL CELLS; FEMALE; HEALTH; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; OVARY; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUMOR MARKERS, BIOLOGICAL;

EID: 79952702757     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-97     Document Type: Article

References (50)

1. Permuth-Wey J, Sellers TA. Epidemiology of ovarian cancer. Methods Mol Biol 2009, 472:413-437. full_text, 19107446.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008, 58(2):71-96. 10.3322/CA.2007.0010, 18287387.
3. Shimizu Y, Kamoi S, Amada S, Akiyama F, Silverberg SG. Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer 1998, 82(5):893-901. 10.1002/(SICI)1097-0142(19980301)82:5<893::AID-CNCR14>3.0.CO;2-W, 9486579.
4. Shih Ie M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004, 164(5):1511-1518. 10.1016/S0002-9440(10)63708-X, 1615664, 15111296.
5. Zorn KK, Bonome T, Gangi L, Chandramouli GV, Awtrey CS, Gardner GJ, Barrett JC, Boyd J, Birrer MJ. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 2005, 11(18):6422-6430. 10.1158/1078-0432.CCR-05-0508, 16166416.
6. Kobel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008, 5(12):e232. 10.1371/journal.pmed.0050232, 2592352, 19053170.
7. Song H, Ramus SJ, Tyrer J, Bolton KL, Gentry-Maharaj A, Wozniak E, Anton-Culver H, Chang-Claude J, Cramer DW, DiCioccio R, et al. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet 2009, 41(9):996-1000. 10.1038/ng.424, 2844110, 19648919.
8. Schwartz DR, Kardia SL, Shedden KA, Kuick R, Michailidis G, Taylor JM, Misek DE, Wu R, Zhai Y, Darrah DM, et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 2002, 62(16):4722-4729.
9. White NM, Mathews M, Yousef GM, Prizada A, Popadiuk C, Dore JJ. KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma. Br J Cancer 2009, 101(7):1107-1113. 10.1038/sj.bjc.6605280, 2768090, 19707197.
10. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004, 4(7):540-550. 10.1038/nrc1388, 15229479.
11. Barbieri F, Bajetto A, Florio T. Role of chemokine network in the development and progression of ovarian cancer: a potential novel pharmacological target. J Oncol 2010, 2010:426956. 2798669, 20049170.
12. Lazennec G, Richmond A. Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med 2010, 16(3):133-144. 10.1016/j.molmed.2010.01.003, 2840699, 20163989.
13. Wilson J, Balkwill F. The role of cytokines in the epithelial cancer microenvironment. Semin Cancer Biol 2002, 12(2):113-120. 10.1006/scbi.2001.0419, 12027583.
14. Kryczek I, Wei S, Keller E, Liu R, Zou W. Stromal derived factor (SDF-1/CXCL12) and human tumor pathogenesis. Am J Physiol Cell Physiol 2007, 292:C987-95. 10.1152/ajpcell.00406.2006, 16943240.
15. Zou W, Machelon V, Coulomb-L'Hermine A, Borvak J, Nome F, Isaeva T, Wei S, Krzysiek R, Durand-Gasselin I, Gordon A, et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 2001, 7(12):1339-1346. 10.1038/nm1201-1339, 11726975.
16. Scotton CJ, Wilson JL, Scott K, Stamp G, Wilbanks GD, Fricker S, Bridger G, Balkwill FR. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res 2002, 62(20):5930-5938.
17. Kryczek I, Lange A, Mottram P, Alvarez X, Cheng P, Hogan M, Moons L, Wei S, Zou L, Machelon V, et al. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res 2005, 65(2):465-472.
18. Scotton CJ, Wilson JL, Milliken D, Stamp G, Balkwill FR. Epithelial cancer cell migration: a role for chemokine receptors?. Cancer Res 2001, 61(13):4961-4965.
19. Kajiyama H, Shibata K, Terauchi M, Ino K, Nawa A, Kikkawa F. Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int J Cancer 2008, 122(1):91-99. 10.1002/ijc.23083, 17893878.
20. Barbolina MV, Kim M, Liu Y, Shepard J, Belmadani A, Miller RJ, Shea LD, Stack MS. Microenvironmental regulation of chemokine (C-X-C-motif) receptor 4 in ovarian carcinoma. Mol Cancer Res 2010, 8(5):653-664. 10.1158/1541-7786.MCR-09-0463, 20460402.
21. Pils D, Pinter A, Reibenwein J, Alfanz A, Horak P, Schmid BC, Hefler L, Horvat R, Reinthaller A, Zeillinger R, et al. In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway. Br J Cancer 2007, 96(3):485-491. 10.1038/sj.bjc.6603581, 2360022, 17245339.
22. Jiang YP, Wu XH, Shi B, Wu WX, Yin GR. Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: an independent prognostic factor for tumor progression. Gynecol Oncol 2006, 103(1):226-233. 10.1016/j.ygyno.2006.02.036, 16631235.
23. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 2001, 22(2):255-288. 10.1210/er.22.2.255, 11294827.
24. Karst AM, Drapkin R. Ovarian cancer pathogenesis: a model in evolution. J Oncol 2010, 2010:932371. 2739011, 19746182.
25. Camilleri-Broet S, Hardy-Bessard AC, Le Tourneau A, Paraiso D, Levrel O, Leduc B, Bain S, Orfeuvre H, Audouin J, Pujade-Lauraine E. HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group. Ann Oncol 2004, 15(1):104-112. 10.1093/annonc/mdh021, 14679128.
26. Tuefferd M, Couturier J, Penault-Llorca F, Vincent-Salomon A, Broet P, Guastalla JP, Allouache D, Combe M, Weber B, Pujade-Lauraine E, et al. HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PLoS One 2007, 2(11):e1138. 10.1371/journal.pone.0001138, 2042515, 17987122.
27. du Bois A, Herrstedt J, Hardy-Bessard AC, Muller HH, Harter P, Kristensen G, Joly F, Huober J, Avall-Lundqvist E, Weber B, et al. Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J Clin Oncol 2010, 28:4162-4169. 10.1200/JCO.2009.27.4696, 20733132.
28. Drapkin R, Crum CP, Hecht JL. Expression of candidate tumor markers in ovarian carcinoma and benign ovary: evidence for a link between epithelial phenotype and neoplasia. Hum Pathol 2004, 35(8):1014-1021. 10.1016/j.humpath.2004.04.014, 15297969.
29. Redjimi N, Gaudin F, Touboul C, Emilie D, Pallardy M, Biola-Vidamment A, Fernandez H, Prevot S, Balabanian K, Machelon V. Identification of glucocorticoid-induced leucine zipper as a key regulator of tumor cell proliferation in epithelial ovarian cancer. Mol Cancer 2009, 8:83. 10.1186/1476-4598-8-83, 2763858, 19814803.
30. Coulomb-L'Hermin A, Amara A, Schiff C, Durand-Gasselin I, Foussat A, Delaunay T, Chaouat G, Capron F, Ledee N, Galanaud P, et al. Stromal cell-derived factor 1 (SDF-1) and antenatal human B cell lymphopoiesis: expression of SDF-1 by mesothelial cells and biliary ductal plate epithelial cells. Proc Natl Acad Sci USA 1999, 96(15):8585-8590. 17560, 10411919.
31. Balabanian K, Couderc J, Bouchet-Delbos L, Amara A, Berrebi D, Foussat A, Baleux F, Portier A, Durand-Gasselin I, Coffman RL, et al. Role of the chemokine stromal cell-derived factor 1 in autoantibody production and nephritis in murine lupus. J Immunol 2003, 170(6):3392-3400.
32. Kryczek I, Frydman N, Gaudin F, Krzysiek R, Fanchin R, Emilie D, Chouaib S, Zou W, Machelon V. The chemokine SDF-1/CXCL12 contributes to T lymphocyte recruitment in human pre-ovulatory follicles and coordinates with lymphocytes to increase granulosa cell survival and embryo quality. Am J Reprod Immunol 2005, 54(5):270-283. 10.1111/j.1600-0897.2005.00307.x, 16212649.
33. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121(3):335-348. 10.1016/j.cell.2005.02.034, 15882617.
34. Levanon K, Ng V, Piao HY, Zhang Y, Chang MC, Roh MH, Kindelberger DW, Hirsch MS, Crum CP, Marto JA, et al. Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. Oncogene 2010, 29(8):1103-1113. 10.1038/onc.2009.402, 2829112, 19935705.
35. Naora H, Montell DJ. Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer 2005, 5(5):355-366. 10.1038/nrc1611, 15864277.
36. Wendt MK, Johanesen PA, Kang-Decker N, Binion DG, Shah V, Dwinell MB. Silencing of epithelial CXCL12 expression by DNA hypermethylation promotes colonic carcinoma metastasis. Oncogene 2006, 25(36):4986-4997. 10.1038/sj.onc.1209505, 16568088.
37. Zhou W, Jiang Z, Liu N, Xu F, Wen P, Liu Y, Zhong W, Song X, Chang X, Zhang X, et al. Down-regulation of CXCL12 mRNA expression by promoter hypermethylation and its association with metastatic progression in human breast carcinomas. J Cancer Res Clin Oncol 2009, 135(1):91-102. 10.1007/s00432-008-0435-x, 18670789.
38. Akishima-Fukasawa Y, Nakanishi Y, Ino Y, Moriya Y, Kanai Y, Hirohashi S. Prognostic significance of CXCL12 expression in patients with colorectal carcinoma. Am J Clin Pathol 2009, 132(2):202-210. 10.1309/AJCPK35VZJEWCUTL, 19605814.
39. Liang JJ, Zhu S, Bruggeman R, Zaino R, Evans D, Fleming JB, Gomez HF, Zander DS, Wang H. High levels of expression of human stromal cell-derived factor-1 are associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2010, 19(10):2598-2604. 10.1158/1055-9965.EPI-10-0405, 20732965.
40. Hassan S, Ferrario C, Saragovi U, Quenneville L, Gaboury L, Baccarelli A, Salvucci O, Basik M. The influence of tumor-host interactions in the stromal cell-derived factor-1/CXCR4 ligand/receptor axis in determining metastatic risk in breast cancer. Am J Pathol 2009, 175(1):66-73. 10.2353/ajpath.2009.080948, 2708795, 19497995.
41. Sasaki K, Natsugoe S, Ishigami S, Matsumoto M, Okumura H, Setoyama T, Uchikado Y, Kita Y, Tamotsu K, Hanazono K, et al. Expression of CXCL12 and its receptor CXCR4 in esophageal squamous cell carcinoma. Oncol Rep 2009, 21(1):65-71.
42. Gelmini S, Mangoni M, Castiglione F, Beltrami C, Pieralli A, Andersson KL, Fambrini M, Taddei GL, Serio M, Orlando C. The CXCR4/CXCL12 axis in endometrial cancer. Clin Exp Metastasis 2009, 26(3):261-268. 10.1007/s10585-009-9240-4, 19199057.
43. Gilbert DC, Chandler I, McIntyre A, Goddard NC, Gabe R, Huddart RA, Shipley J. Clinical and biological significance of CXCL12 and CXCR4 expression in adult testes and germ cell tumours of adults and adolescents. J Pathol 2009, 217(1):94-102. 10.1002/path.2436, 18839394.
44. Barbero S, Bonavia R, Bajetto A, Porcile C, Pirani P, Ravetti JL, Zona GL, Spaziante R, Florio T, Schettini G. Stromal cell-derived factor 1 alpha stimulates human glioblastoma cell growth through the activation of both extracellular signal-regulated kinases 1/2 and Akt. Cancer Res 2003, 63(8):1969-1974.
45. Lis R, Touboul C, Mirshahi P, Ali F, Mathew S, Nolan DJ, Maleki TM, Abdalla SA, Raynaud CM, Querleu D, et al. Tumor associated mesenchymal stem cells protects ovarian cancer cells from hyperthermia through CXCL12. Int J Cancer 2010, 128:715-725.
46. Laguri C, Arenzana-Seisdedos F, Lortat-Jacob H. Relationships between glycosaminoglycan and receptor binding sites in chemokines-the CXCL12 example. Carbohydr Res 2008, 343(12):2018-2023. 10.1016/j.carres.2008.01.047, 18334249.
47. Balabanian K, Lagane B, Infantino S, Chow KY, Harriague J, Moepps B, Arenzana-Seisdedos F, Thelen M, Bachelerie F. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem 2005, 280(42):35760-35766. 10.1074/jbc.M508234200, 16107333.
48. Thelen M, Thelen S. CXCR7, CXCR4 and CXCL12: an eccentric trio ?. J Neuroimmunol 2008, 198(1-2):9-13. 10.1016/j.jneuroim.2008.04.020, 18533280.
49. Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z, Penfold ME, Sunshine MJ, Littman DR, Kuo CJ, et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 2006, 203(9):2201-2213. 10.1084/jem.20052144, 2118398, 16940167.
50. Mirisola V, Zuccarino A, Bachmeier BE, Sormani MP, Falter J, Nerlich A, Pfeffer U. CXCL12/SDF1 expression by breast cancers is an independent prognostic marker of disease-free and overall survival. Eur J Cancer 2009, 45(14):2579-2587. 10.1016/j.ejca.2009.06.026, 19646861.